NEUP Neuphoria Therapeutics Inc. Earnings per share growth rate in current year

The annual EPS volatility demonstrates the monetization potential of neurotherapy for treating depression and cognitive impairment for Neuphoria Therapeutics Inc. (NEUP). The value 0.00 describes the current profit level, supported by successful clinical trials of anti-anxiety drugs. The Australian biotech relies on organic growth and targeted fundraising, completely ruling out the possibility of mergers with other market players.
Comprehensive metric breakdowns and analytics for Neuphoria (NEUP)

This indicator measures the annual percentage change in net income per share, reflecting the intensity of the issuer's cash flows. By analyzing the YoY earnings per share dynamics, an investor assesses the business scaling speed. For Neuphoria Therapeutics Inc. (NEUP), such fluctuations depend on the success of developing drugs for the precise modulation of brain ion channels. Sharp spikes on the chart signal speculative overheating, while a stable trend confirms the fundamental resilience of the asset.